Lyell Immunopharma, Inc.

Equities

LYEL

US55083R1041

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 21/05/2024 BST			5-day change	1st Jan Change
2.61 ^USD	-2.25%		+2.76%	+34.54%

05-06	Sector Update: Health Care Stocks Higher in Late Afternoon Trading	MT
05-06	Lyell Immunopharma Shares Rise After Q1 Net Loss Narrows	MT

Lyell Immunopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022

November 08, 2022 at 09:05 pm

Lyell Immunopharma, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was USD 0.003 million compared to USD 2.76 million a year ago. Net loss was USD 70.25 million compared to USD 48.88 million a year ago.
For the nine months, sales was USD 36.3 million compared to USD 7.83 million a year ago. Net loss was USD 174.72 million compared to USD 166.51 million a year ago.

Latest news about Lyell Immunopharma, Inc.

Sector Update: Health Care Stocks Higher in Late Afternoon Trading	05-06	MT
Lyell Immunopharma Shares Rise After Q1 Net Loss Narrows	05-06	MT
Earnings Flash (LYEL) LYELL IMMUNOPHARMA Reports Q1 Revenue $3,000	05-06	MT
Lyell Immunopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-06	CI
North American Morning Briefing : Stock Futures -2-	03-04	DJ
Lyell Immunopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-28	CI
Earnings Flash (LYEL) LYELL IMMUNOPHARMA Reports Q4 Revenue $13,000	02-28	MT
Lyell Immunopharma, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-28	CI
Phoenix Biotech Acquisition Corp. completed the acquisition of CERo Therapeutics, Inc.	02-13	CI
MaxCyte's strategic platform licences redeem otherwise modest results	01-09	AN
Lyell Immunopharma, Inc.(NasdaqGS:LYEL) dropped from S&P Biotechnology Select Industry Index	12-18	CI
HC Wainwright Trims Lyell Immunopharma's Price Target to $8 From $9, Maintains Buy Rating	11-09	MT
Earnings Flash (LYEL) LYELL IMMUNOPHARMA Posts Q3 Revenue $25,000	11-07	MT
Lyell Immunopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07	CI
Lyell Immunopharma, Inc. Presents New Nonclinical Data at 38th Annual Meeting of SITC on Innovations Designed to Shorten Tumor Infiltrating Lymphocyte Manufacturing, LYL119 as Well as Data on New Technologies and Design of its Two Clinical Trials in Progress	31/10/23	CI
Cellares and Lyell to Evaluate Automated Manufacturing of Lyell's Car T-Cell Therapy on Cellares' Cell Shuttle Platform	11/09/23	CI
North American Morning Briefing : Investors Look -2-	29/08/23	DJ
JPMorgan Downgrades Lyell Immunopharma to Neutral From Overweight, Adjusts Price Target to $5 From $15	28/08/23	MT
Insider Sell: Lyell Immunopharma	17/08/23	MT
Earnings Flash (LYEL) LYELL IMMUNOPHARMA Reports Q2 Revenue $27,000	08/08/23	MT
Lyell Immunopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	08/08/23	CI
MaxCyte Signs Strategic Platform License with Lyell Immunopharma	06/07/23	MT
MaxCyte inks strategic platform license with Lyell Immunopharma	06/07/23	AN
Lyell Immunopharma Names Chief Business Officer	05/07/23	MT
Lyell Immunopharma, Inc. Appoints Matthew Lang as Chief Business Officer	05/07/23	CI

Chart Lyell Immunopharma, Inc.

Duration

Period

More charts

Company Profile

Lyell Immunopharma, Inc. is a clinical-stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors. The Company is engaged in enrolling a Phase I clinical trial evaluating a ROR1-targeted CAR T-cell therapy in patients with relapsed refractory triple-negative breast cancer and non-small cell lung cancer (NSCLC) and a second Phase I clinical trial evaluating reprogrammed tumor infiltrating lymphocytes (TIL) in patients with advanced melanoma, NSCLC and colorectal cancer. The technologies powering its product candidates are designed to address barriers that limit consistent and long-lasting responses to cell therapy for solid tumors: T-cell exhaustion and lack of durable stemness, which includes the ability to persist and self-renew to drive durable tumor cytotoxicity. The Company is applying its proprietary ex vivo genetic and epigenetic reprogramming technologies to address these barriers in order to develop medicines.

Sector

Biotechnology & Medical Research

Calendar

14/06/2024 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Lyell Immunopharma, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.61 USD

Average target price

6.333 USD

Spread / Average Target

+142.66%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
LYELL IMMUNOPHARMA, INC.	+34.54%	681M
VERTEX PHARMACEUTICALS INCORPORATED	+8.63%	115B
REGENERON PHARMACEUTICALS, INC.	+13.17%	107B
BIONTECH SE	-12.76%	22.31B
ARGENX SE	-3.99%	21.6B
BEIGENE, LTD.	-7.19%	18.23B
WUXI APPTEC CO., LTD.	-39.93%	17.62B
NEUROCRINE BIOSCIENCES, INC.	+6.67%	14.26B
SAREPTA THERAPEUTICS, INC.	+33.90%	12.37B
LEGEND BIOTECH CORPORATION	-28.60%	8.28B

Bio Therapeutic Drugs